ARMS Pharmaceutical LLC, a drug development company headquartered in Cleveland, Ohio, was founded to develop a portfolio of products targeted at respiratory tract health, a $12 billion market.
ARMS has a strong intellectual property portfolio and has carried out in vitro studies and clinical trials on ARMS-I, it's leading drug candidate, with the goal of preventing and treating viral upper respiratory infections (“vURTIs”).
ARMS Pharmaceutical plans to pursue approval through the New Drug regulatory pathway
The company has obtained method of use and composition patents
The company has in vitro data on ARMS-I against a variety of upper respiratory viruses
ARMS Pharmaceutical plans to eventually seek FDA approval of ARMS-I, as a drug for the treatment and/or prevention of specific viral upper respiratory tract infections (collectively, "vURTIs").
ARMS-I's is being studied for patients exposed to airborne pathogens that cause vURTIs, as well as individuals who develop early stage symptoms of vURTI’s.
ARMS-I is administered through a portable oral spray that is applied before or during exposure to airborne pathogens. In short, ARMS-I is being designed as an antiviral drug to provide “first response” prophylaxis and potential treatment against vURTIs.